Maze Therapeutics (MAZE) Gross Margin (2026)
Maze Therapeutics (MAZE) reported Gross Margin of 91.04% for Q1 2026.
Maze Therapeutics (MAZE) Gross Margin (2026) Analysis & Trends
Maze Therapeutics (MAZE) has 1 years of Gross Margin data on file, last reported at 91.04% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | 91.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.04% |